The effect of sustained virological response by direct-acting antivirals on insulin resistance and diabetes mellitus in patients with chronic hepatitis C

被引：14
|
作者：
Adinolfi, Luigi Elio [1 ]
Rinaldi, Luca [1 ]
Marrone, Aldo [1 ]
Giordano, Mauro [1 ]
机构：
[1] Univ Campania L Vanvitelli, Dept Med Surg Neurol Metab & Geriatr Sci, Naples, Italy
来源：
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY | 2018年 / 16卷 / 08期
关键词：
DAAs; chronic hepatitis C; insulin resistance; type 2 diabetes mellitus; GLYCEMIC CONTROL; IMPROVEMENT; INFECTION; HCV;
D O I：
10.1080/14787210.2018.1505500
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：595 / 597
页数：3
相关论文
共 50 条
  • [41] Effect of achieving sustained virological response with direct-acting antiviral agents on glycemic control in diabetic patients with chronic hepatitis C infection
    Mohamed El-Kassas
    Runia El-Folly
    Maram Aboromia
    Heba Aly
    Mohamed Bahgat
    Mostafa Hamed
    Egyptian Liver Journal, 12
  • [42] Hepatocellular carcinoma risk in hepatitis C stage-3 fibrosis after sustained virological response with direct-acting antivirals
    Sanchez-Azofra, Maria
    Fernandez, Inmaculada
    Garcia-Buey, Maria L.
    Dominguez-Dominguez, Lourdes
    Fernandez-Rodriguez, Conrado M.
    Mancebo, Antonio
    Bonet, Lucia
    Ryan, Pablo
    Gea, Francisco
    Diaz-Sanchez, Antonio
    Garcia-Mayor, Marian
    Martin-Carbonero, Luz
    Castillo, Pilar
    Manzano, Maria L.
    Gonzalez-Moreno, Leticia
    Pulido, Federico
    Gutierrez, Maria L.
    Moreno, Jose M.
    Garcia-Amengual, Irene M.
    Cuevas, Guillermo
    Guerrero, Antonio
    Rivero-Fernandez, Miguel
    Portales, Maria E.
    Montes, Maria L.
    Olveira, Antonio
    LIVER INTERNATIONAL, 2021, 41 (12) : 2885 - 2891
  • [43] Histological improvement of fibrosis in patients with hepatitis C who achieved a 5-year sustained virological response to treatment with direct-acting antivirals
    Takayuki Iwamoto
    Yasutoshi Nozaki
    Takanori Inoue
    Takahiro Suda
    Rui Mizumoto
    Yuki Arimoto
    Takashi Ohta
    Shinjiro Yamaguchi
    Yoshiki Ito
    Yoshiko Sudo
    Michiko Yoshimura
    Machiko Kai
    Yoichi Sasaki
    Yuki Tahata
    Hayato Hikita
    Tetsuo Takehara
    Hideki Hagiwara
    Journal of Gastroenterology, 2025, 60 (2) : 197 - 209
  • [44] Hepatitis C virus resistance to the new direct-acting antivirals
    Esposito, Isabella
    Trinks, Julieta
    Soriano, Vicente
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (10) : 1197 - 1209
  • [45] Sustained Virologic Response and Costs Associated with Direct-Acting Antivirals for Chronic Hepatitis C Infection in Oklahoma Medicaid
    Pham, Timothy T.
    Keast, Shellie L.
    Farmer, Kevin C.
    Thompson, David M.
    Rathbun, Chris
    Nesser, Nancy J.
    Holderread, Bethany P.
    Skrepnek, Grant H.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2018, 24 (07): : 664 - 676
  • [46] Virological Efficacy of New, Oral, Direct-Acting Antivirals in Hepatitis C Patients With Mixed Cryoglobulinemia
    Mittal, Rasham
    Sahota, Amandeep
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S897 - S897
  • [47] New direct-acting antivirals for the treatment of chronic hepatitis C
    Jeong, Sook-Hyang
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2015, 58 (12): : 1154 - 1158
  • [48] Chronic Hepatitis C in Elderly Patients: Current Evidence with Direct-Acting Antivirals
    Manan A. Jhaveri
    Vignan Manne
    Kris V. Kowdley
    Drugs & Aging, 2018, 35 : 117 - 122
  • [49] Direct-acting antivirals for children and adolescents with chronic hepatitis C
    Indolfi, Giuseppe
    Serranti, Daniele
    Resti, Massimo
    LANCET CHILD & ADOLESCENT HEALTH, 2018, 2 (04): : 298 - 304
  • [50] Safety of direct-acting antivirals in the treatment of chronic hepatitis C
    Ridruejo, Ezequiel
    EXPERT OPINION ON DRUG SAFETY, 2014, 13 (03) : 307 - 319
12345